Prima BioMed replaces director


By Dylan Bushell-Embling
Thursday, 13 February, 2014

Prima BioMed (ASX:PRR) has added former investment banker Pete Meyers to its board as a non-executive director.

Meyers is currently CFO of TetraLogic Pharmaceuticals, where he led the execution of its IPO in December.

Before joining TetraLogic, Meyers was an investment banker. Notable roles in the industry include co-head of global healthcare investment banking at Deutsche Bank in New York. He also held various roles at Dillon, Read & Co and Credit Suisse First Boston.

“I believe Pete’s depth of experience in the US capital markets, his network in the biotech community and his expertise advising healthcare companies will serve Prima well,” Prima Chairperson Lucy Turnbull said.

Meyers will be replacing Dr Richard Hammel, who is stepping down from the board after serving since January 2005.

Prima BioMed (ASX:PRR) shares were trading 4.08% higher at $0.051 as of around 2 pm on Tuesday.

Related News

Diabetes drug reduces knee arthritis pain in overweight patients

A common diabetes drug can reduce the pain of people with knee osteoarthritis and overweight or...

Prenatal stress leaves a molecular mark on newborns

An international study has uncovered how stress experienced during pregnancy can affect newborns...

More effective antibiotic found for Lyme disease

Researchers have found that piperacillin, an antibiotic in the same class as penicillin,...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd